Constitutive activation of Ras-proteins plays an important role in the development of aggressive colorectal carcinomas and several other types of cancer. Despite some progress in recent years in the case of K-Ras4B, until now not a single small molecule inhibitor has been identified that binds efficiently to Rheb and interrupts the protein–protein interactions with mTOR. We describe here a complementary approach that aims at inhibiting membrane insertion of Rheb and related Ras proteins by masking the crucial C-terminal CaaX-box with peptidomimetic receptors identified in combinatorial solid-phase libraries.

Binding of Leu-enkephalin and [RhIII(η5-Cp*)(η6-Tyr1)]Leu-enkephalin to the recently published crystal structures of the μ- and δ-opioid receptor is studied. Docking of free Leu-enkephalin reveals two preferred conformations, one of which suggests an alternative binding site for the tyrosine residue. Furthermore, the three-dimensional solution structure of [RhIII(η5-Cp*)(η6-Tyr1)]Leu-enkephalin was solved by using 2D NMR spectroscopic techniques.

The bioconjugation of organometallic complexes with peptides has proven to be a novel approach for drug discovery. We report the facile and chemoselective reaction of tyrosine-containing G-protein-coupled receptor (GPCR) peptides with [Cp*Rh(H2O)3](OTf)2, in water, at room temperature, and at pH 5–6. We have focused on three important GPCR peptides; namely, [Tyr1]-leu-enkephalin, [Tyr4]-neurotensin(8-13), and [Tyr3]-octreotide, each of which has a different position for the tyrosine residue, together with competing functionalities. Importantly, all other functional groups present, i.e., amino, carboxyl, disulfide, phenyl, and indole, were not prominent sites of reactivity by the Cp*Rh tris aqua complex. Furthermore, the influence of the Cp*Rh moiety on the structure of [Tyr3]-octreotide was characterized by 2D NMR, resulting in the first representative structure of an organometallic-peptide complex. The biological consequences of these Cp*Rh-peptide complexes, with respect to GPCR binding and growth inhibition of MCF7 and HT29 cancer cells, will be presented for [(η6-Cp*Rh-Tyr1)-leu-enkephalin](OTf)2 and [(η6-Cp*Rh-Tyr3)-octreotide](OTf)2.

Psb27 is a membrane-extrinsic subunit of photosystem II (PSII) where it is involved in the assembly and maintenance of this large membrane protein complex that catalyzes one of the key reactions in the biosphere, the light-induced oxidation of water. Here, we report for the first time the structure of Psb27 that was not observed in the previous crystal structures of PSII due to its transient binding mode. The Psb27 structure shows that the core of the protein is a right-handed four-helix bundle with an up−down−up−down topology. The electrostatic potential of the surface generated by the amphipathic helices shows a dipolar distribution which fits perfectly to the major PsbO binding site on the PSII complex. Moreover, the presented docking model could explain the function of Psb27, which prevents the binding of PsbO to facilitate the assembly of the Mn4Ca cluster.

Binding of Leu-enkephalin and [RhIII(η5-Cp*)(η6-Tyr1)]Leu-enkephalin to the recently published crystal structures of the μ- and δ-opioid receptor is studied. Docking of free Leu-enkephalin reveals two preferred conformations, one of which suggests an alternative binding site for the tyrosine residue. Furthermore, the three-dimensional solution structure of [RhIII(η5-Cp*)(η6-Tyr1)]Leu-enkephalin was solved by using 2D NMR spectroscopic techniques.